The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of
telbivudine by maintained suppression of hepatitis B virus (HBV) DNA (<=300 copies/ml or
60IU/ml, undetectable by current polymerase chain reaction (PCR) - based assays) in HBeAg
positive/negative patients at physician's general practice.